ImaRx Therapeutics, Inc. (IMRX) and Microbix Biosystems Inc. have signed a Letter of Intent to manufacture urokinase and further explore development for additional indications. Urokinase is an FDA approved drug currently marketed under the brand name Abbokinase(R). This product is a thrombolytic agent that is used to dissolve blood clots that have formed in certain blood vessels. It has been used to treat patients in the United States for over 20 years.
ImaRx intends to transfer the manufacturing process and NDA to Microbix creating a new source for urokinase. This new supply of urokinase will allow ImaRx to continue to serve its current customers beyond its existing inventory of manufactured drug product. It also provides the opportunity to expand sales to additional vascular physicians and acute care institutions and to explore clinical development of urokinase for additional vascular indications. In addition, Microbix receives the right to further develop the drug for certain new indications in catheter clearance and prophylaxis of serious catheter related complications such as blood stream infections and venous thrombi. Microbix' future targets are also expected to include opportunities in oncology and ophthalmology. Microbix is believed to be the only supplier capable of producing urokinase on a commercial scale at its production facility in Toronto.
KNOBIAS DISCLAIMER: All statements made in this article were made by the Company and do not in any way reflect the opinions of Knobias. Knobias is not a registered broker-dealer, nor investment advisor, and does not endorse or recommend any securities mentioned. This story is provided for informational purposes only and is not intended for trading purposes. Knobias shall not be liable for any actions taken in reliance of any information provided herein. Republication or redistribution of Knobias content is expressly prohibited without prior written consent of Knobias.com, LLC.
ABOUT KNOBIAS: Knobias is a premier financial information provider of trading and investing data covering all U.S. equities for investors and security professionals. Knobias is best described by its three major components: Real-time desktop applications providing quotes, charts, level 2, analysis etc.; Knobias RAiDAR providing thousands of real-time news stories, alerts and documents daily; Knobias fundamentals providing a comprehensive database of fundamental research information.
If your company wishes to participate in the EventX newswire, please contact Knobias: http://www.knobias.com
Knobias.com, LLC 601-978-3399 601-978-3675 info@knobias.com www.knobias.com/cmtx
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
|
|
